CLINICAL Data has announced it will present at the 2009 Future Leaders in the Biotech Industry Conference held on 2 April 2009.
27/03/2009
THE RUDD Government has announced cancer patients in Bendigo, Wodonga, Coffs Harbour, Port Macquarie and Hobart will be able to benefit from new cancer treatments as part of clinical cancer trials.
31/08/2009
PRANA Biotechnology says Dr Craig Ritchie of Imperial College, London, presented an update on the clinical efficacy of its PBT2 drug at the 2009 International Conference on Alzheimer’s Disease.
13/07/2009
TGEN CLINICAL Research Services at Scottsdale Healthcare has announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands
29/09/2009
LIVING Cell Technologies has formally opened its new designated pathogen free pig breeding facility in Invercargill, Southland, New Zealand.
02/07/2009
The National Health and Medical Research Council (NHMRC) has announced that clinical trials involving animal to human transplantation (xenotransplantation) would be allowed to proceed, once stringent regulatory and surveillance frameworks have been put in place.
11/12/2009
EcoBiotics has announced that following promising results in treating inoperable tumours in horses and dogs, it was fast-tracking its development of a cancer drug, EBC-46, into human clinical trials.
05/11/2009
A NEW drug is being tested by TGen Clinical Research Services (TCRS) that may offer broad potential to treat solid tumours.
30/01/2009
Brumby’s Labor Government has streamlined the ethical review process for clinical trials, making medical research into potentially lifesaving treatments easier to conduct in Victoria.
05/11/2009
THE COMMITTEE for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic nonsmall cell lung cancer (NSCLC).
28/07/2009
CYTOPIA has filed an Investigational New Drug Application with the US Food and Drug Administration for its orally active JAK2 inhibitor CYT387.
24/06/2009
BIONOMICS says it will be proceeding with the next clinical trial of its tumour-treating BNC105 vascular disrupting agent in the US.
02/07/2009
PERKINELMER has announced it has acquired the genetic screening business of Surendra Genetic Labs, a laboratory in India focusing on fetal, maternal and newborn health.
09/09/2009
PHARMACYCLICS has announced it is beginning treatment on patients in a Phase I dose-escalation study to evaluate the safety and tolerability of PCI-32765.
15/04/2009
THE Blanchette Rockefeller Neurosciences Institute (BRNI) has received a green light from the FDA to enter Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients.
24/04/2009
MICROSOFT has announced the winners of its 2009 Microsoft Pharmaceutical and Life Sciences Innovation Awards.
23/06/2009
A NEW DRUG designed to “seek and destroy” common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
06/10/2009
THE American Society of Clinical Oncology (ASCO) and theAmerican Urological Association have released a repost suggesting healthy men with a prostate specific antigen score of 3.0 or lower should discuss taking 5-alpha reductase inhibitors (5-ARIs) to decrease their risk of developing prostate cancer.
02/03/2009
LIVING Cell Technologies says New Zealand has authorised the Phase I/IIa clinical trial of DIABECELL for insulin dependent diabetes.
24/06/2009
BRISBANE dermatology company Peplin has announced a definitive merger agreement whereby LEO Pharma (LEO) will acquire all outstanding securities of Peplin for approximately US$287.5 million (currently A$348.4 million) in cash.
07/09/2009